Search

Your search keyword '"Cao, Lizhi"' showing total 16 results
Start Over Author "Cao, Lizhi" Publication Year Range Last 3 years
16 results on '"Cao, Lizhi"'

6. Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors

Author

Luke, Jason J., primary, Johnson, Melissa, additional, Tolcher, Anthony, additional, Chen, Christopher T., additional, Dai, Tong, additional, Curti, Brendan D., additional, El-Khoueiry, Anthony, additional, Sznol, Mario, additional, Henick, Brian S., additional, Horak, Christine, additional, Jayaraman, Pushpa, additional, Cole, Christopher B., additional, Wilson, Dawn, additional, Cao, Lizhi, additional, Peng, Li, additional, Feltquate, David, additional, Lathers, Deanne, additional, and Sharma, Manish R., additional

Published
2023
Full Text
View/download PDF

7. Long-term pegylated growth hormone for children with growth hormone deficiency: a large, prospective, real-world study

Author

Hou, Ling, primary, Huang, Ke, additional, Gong, Chunxiu, additional, Luo, Feihong, additional, Wei, Haiyan, additional, Liang, Liyang, additional, Du, Hongwei, additional, Zhang, Jianping, additional, Zhong, Yan, additional, Chen, Ruimin, additional, Chen, Xinran, additional, Pan, Jiayan, additional, Jin, Xianjiang, additional, Zeng, Ting, additional, Liao, Wei, additional, Liu, Deyun, additional, Lan, Dan, additional, Zhu, Shunye, additional, Dong, Zhiya, additional, Ma, Huamei, additional, Yang, Yu, additional, Xiong, Feng, additional, MB, Ping Lu, additional, Cheng, Shengquan, additional, Gu, Xuefan, additional, Jin, Runming, additional, Liu, Yu, additional, Wu, Jinzhun, additional, Xu, Xu, additional, Chen, Linqi, additional, Dong, Qin, additional, Pan, Hui, additional, Su, Zhe, additional, Liu, Lijun, additional, Luo, Xiaoming, additional, Ni, Shining, additional, Chen, Zhihong, additional, Hu, Yuhua, additional, Wang, Chunlin, additional, Liu, Jing, additional, Liu, Li, additional, Lu, Biao, additional, Wang, Xinli, additional, Wang, Yunfeng, additional, Yang, Fan, additional, Zhang, Manyan, additional, Cao, Lizhi, additional, Liu, GeLi, additional, Yao, Hui, additional, Zhang, Yaqin, additional, Dai, Mingjuan, additional, Li, Guimei, additional, Li, Li, additional, Liu, Yanjie, additional, Wang, Kan, additional, Xiao, Yanfeng, additional, Zhang, Xingxing, additional, Dong, Junhua, additional, Gu, Zaiyan, additional, Ying, Lirong, additional, Huang, Feng, additional, Liu, Yanling, additional, Liu, Zheng, additional, Ye, Jin, additional, Zhao, Dongmei, additional, Hu, Xu, additional, Jiang, Zhihong, additional, Ye, Kan, additional, Zhu, Hong, additional, Chen, Shaoke, additional, Chen, Xiaobo, additional, Wan, Naijun, additional, Xu, Zhuangjian, additional, Yin, Qingjin, additional, Zhang, Hongxiao, additional, Huang, Xiaodong, additional, Yin, Jianying, additional, Zhang, Huifeng, additional, Li, Pin, additional, Yin, Ping, additional, Fu, Junfen, additional, and Luo, XiaoPing, additional

Published
2023
Full Text
View/download PDF

8. 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)

Author

Sharma, Manish, primary, Lathers, Deanne, additional, Johnson, Melissa, additional, Luke, Jason, additional, Puzanov, Igor, additional, Curti, Brendan, additional, Chen, Christopher, additional, El-Khoueiry, Anthony, additional, Henick, Brian, additional, Callahan, Margaret, additional, Sznol, Mario, additional, Patel, Sandip, additional, Wilson, Dawn, additional, Ricker, Melissa, additional, Cao, Lizhi, additional, Jayaraman, Pushpa, additional, Che, Jenny, additional, Peng, Li, additional, Feltquate, David, additional, and Tolcher, Anthony, additional

Published
2022
Full Text
View/download PDF

9. Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

Author

Jiang, Zhouhong, primary, Chen, Xuefeng, additional, Dong, Guanping, additional, Lou, Yin, additional, Zhang, Jianping, additional, Cheng, Xinran, additional, Pan, Jiayan, additional, Liao, Wei, additional, Wu, Jinzhun, additional, Huang, Xiaodong, additional, Jin, Xianjiang, additional, Liu, Deyun, additional, Zeng, Ting, additional, Zhu, Shunye, additional, Dong, Qin, additional, Luo, Xiaoming, additional, Lan, Dan, additional, Cao, Lizhi, additional, Zhang, Xingxing, additional, Liu, Jing, additional, Dai, Mingjuan, additional, Zhang, Manyan, additional, Liu, Li, additional, Dong, Junhua, additional, Zhao, Dongmei, additional, Ni, Shaoqing, additional, and Fu, Junfen, additional

Published
2022
Full Text
View/download PDF

13. Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study

Author

Hou, Ling, Huang, Ke, Gong, Chunxiu, Luo, Feihong, Wei, Haiyan, Liang, Liyang, Du, Hongwei, Zhang, Jianping, Zhong, Yan, Chen, Ruimin, Chen, Xinran, Pan, Jiayan, Jin, Xianjiang, Zeng, Ting, Liao, Wei, Liu, Deyun, Lan, Dan, Zhu, Shunye, Dong, Zhiya, Ma, Huamei, Yang, Yu, Xiong, Feng, Lu, Ping, Cheng, Shengquan, Gu, Xuefan, Jin, Runming, Liu, Yu, Wu, Jinzhun, Xu, Xu, Chen, Linqi, Dong, Qin, Pan, Hui, Su, Zhe, Liu, Lijun, Luo, Xiaoming, Ni, Shining, Chen, Zhihong, Hu, Yuhua, Wang, Chunlin, Liu, Jing, Liu, Li, Lu, Biao, Wang, Xinli, Wang, Yunfeng, Yang, Fan, Zhang, Manyan, Cao, Lizhi, Liu, GeLi, Yao, Hui, Zhan, Yaqin, Dai, Mingjuan, Li, Guimei, Li, Li, Liu, Yanjie, Wang, Kan, Xiao, Yanfeng, Zhang, Xingxing, Dong, Junhua, Gu, Zaiyan, Ying, Lirong, Huang, Feng, Liu, Yanling, Liu, Zheng, Ye, Jin, Zhao, Dongmei, Hu, Xu, Jiang, Zhihong, Ye, Kan, Zhu, Hong, Chen, Shaoke, Chen, Xiaobo, Wan, Naijun, Xu, Zhuangjian, Yin, Qingjin, Zhang, Hongxiao, Huang, Xiaodong, Yin, Jianying, Zhang, Huifeng, Li, Pin, Yin, Ping, Fu, Junfen, and Luo, XiaoPing

Published
2023
Full Text
View/download PDF

14. 843 Development and engineering of human sialidase for degradation of immunosuppressive sialoglycans to treat cancer

Author

Peng Li, Das Abhishek, Xu Lihui, Nerle Sujata, Che Jenny, Autumn Turner, Hui Xu, Sandip A. Shelke, James Broderick, Gatlin Wayne, Cao Lizhi, Robert LeBlanc, and Zakir Siddiquee

Subjects
Pharmacology, Cancer Research, biology, Chemistry, medicine.medical_treatment, Immunology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Sialidase, Mixed lymphocyte reaction, Acquired immune system, Immune system, Cytokine, Oncology, Antigen, Immunity, biology.protein, Cancer research, medicine, Molecular Medicine, Immunology and Allergy, Antibody, RC254-282
Abstract

BackgroundSialoglycans, a type of glycans with a terminal sialic acid, have emerged as a critical glyco-immune checkpoint that impairs antitumor response by inhibiting innate and adaptive immunity. Upregulation of sialoglycans on tumors has been observed for decades and correlates with poor clinical outcomes across many tumor types. We previously showed that targeted desialylation of tumors using a bifunctional sialidase x antibody molecule, consisting of sialidase and a tumor-associated antigen (TAA)-targeting antibody, has led to robust single-agent efficacy in mouse tumor models. In addition to tumor cells, most immune cells present substantially more abundant sialoglycans than non-hematological healthy cells, which may also contribute to immunosuppression. Therefore, we studied the impact of immune cell desialylation and evaluated the therapeutic potential of a newly developed sialidase-Fc fusion (Bi-Sialidase), which lacks a TAA-targeting moiety and consists of engineered human neuraminidase 2 (Neu2) and human IgG1 Fc region, in preclinical mouse tumor models.MethodsThe first generation Neu2 variant was further optimized to improve titers and stability to constructed Bi-Sialidase. Bi-Sialidase’s desialylation potency and impact on immune responses were studied in vitro using various human immune functional assays, including T-cell activation, allogeneic mixed lymphocyte reaction, antibody-dependent cellular cytotoxicity, macrophages polarization/activation, neutrophil activation, and peripheral blood mononuclear cell (PBMC) cytokine release assays. We evaluated its antitumor efficacy in mouse tumor models. Bi-Sialidase’s safety profile was characterized by conducting rat and non-human primate (NHP) toxicology studies.ResultsThe optimized Bi-Sialidase achieved a titer of 2.5 g/L from a 15-day fed-batch Chinese hamster ovary cell culture; in contrast, the wild-type and first-generation Neu2 had no production or a low titer (ConclusionsBi-Sialidase with an optimized Neu2 offers a novel immunomodulatory approach to enhancing T-cell immunity by desialylating immunosuppressive sialoglycans for cancer treatment.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results